


TRANSMITTAL FORM

ENCLOSURES (check all that apply)

- Certificate
JUL 25 2005
of Correction

SIGNATURE OF ATTORNEY OR AGENT

CERTIFICATE OF MAILING

Signature:			
Typed or Printed Name:	Narinder S. Banait	Dated:	July 19/2005
Express Mail Mailing Number (optional):			

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) -0-

Complete if Known

Patent No.:	6,906,237
Issue Date:	June 14, 2005
Application Number	09/905,704
Filing Date	February 27, 2001
First Named Inventor	G. Scott Herron
Examiner Name	Valerie E. Bertoglio
Art Unit	1632
Attorney Docket No.	23946-08185

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None
☒ Deposit Account:

Deposit Account Number

19-2555

Deposit Account Name

Fenwick & West LLP

The Commissioner is authorized to: *(check all that apply)*

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge all required fee(s) or any underpayment of fee(s) due under 37 CFR §1.16 or §1.17 during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity
<p>1. Revenue Recognition</p> <p>Large entities use the percentage of completion method for long-term contracts, recognizing revenue as work progresses. Small entities often use the cost of sales method, recognizing revenue only when the contract is completed.</p>	<p>1. Revenue Recognition</p> <p>Small entities often use the cost of sales method for long-term contracts, recognizing revenue only when the contract is completed.</p>
<p>2. Inventory Valuation</p> <p>Large entities use the FIFO (First In, First Out) method for inventory valuation. Small entities often use the LIFO (Last In, First Out) method.</p>	<p>2. Inventory Valuation</p> <p>Small entities often use the LIFO (Last In, First Out) method for inventory valuation.</p>
<p>3. Depreciation</p> <p>Large entities use the MACRS (Modified Accelerated Cost Recovery System) for depreciation. Small entities often use the straight-line method.</p>	<p>3. Depreciation</p> <p>Small entities often use the straight-line method for depreciation.</p>
<p>4. Bad Debt Expense</p> <p>Large entities use the allowance method for bad debt expense. Small entities often use the direct write-off method.</p>	<p>4. Bad Debt Expense</p> <p>Small entities often use the direct write-off method for bad debt expense.</p>
<p>5. Lease Accounting</p> <p>Large entities use the ASC 842 (Leases) standard for lease accounting. Small entities often use the ASC 840 (Leases) standard.</p>	<p>5. Lease Accounting</p> <p>Small entities often use the ASC 840 (Leases) standard for lease accounting.</p>

<u>Fee</u>	<u>Fee</u>	<u>Fee</u>	<u>Fee</u>	<u>Fee Description</u>	<u>Fee Paid</u>
<u>Code</u>	<u>(\$)</u>	<u>Code</u>	<u>(\$)</u>		

SUBTOTAL (1)	(\$)	-0-
---------------------	-------------	------------

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	<div><div></div>-20**=<div></div> X</div>	<div></div> =	<div></div>
Independent Claims	<div><div></div>-3**=<div></div> X</div>	<div></div> =	<div></div>
Multiple Dependent		<div></div> =	<div></div>

	Large Entity	Small Entity
1. Revenue Recognition	Revenue is recognized when the performance obligation is satisfied, which is when control of the goods or services is transferred to the customer.	Revenue is recognized when the performance obligation is satisfied, which is when control of the goods or services is transferred to the customer.
2. Leases	Leases are classified as either finance leases or operating leases. Finance leases are treated as sales, while operating leases are treated as rentals.	Leases are classified as either finance leases or operating leases. Finance leases are treated as sales, while operating leases are treated as rentals.
3. Intangible Assets	Intangible assets are recognized when they are identifiable and have a measurable value. They are amortized over their useful life.	Intangible assets are recognized when they are identifiable and have a measurable value. They are amortized over their useful life.
4. Goodwill	Goodwill is recognized as the excess of the purchase price over the fair value of the identifiable intangible assets.	Goodwill is recognized as the excess of the purchase price over the fair value of the identifiable intangible assets.
5. Research and Development	Research and development costs are expensed as incurred.	Research and development costs are expensed as incurred.
6. Employee Benefits	Employee benefits are recognized when the employee has rendered service to the company.	Employee benefits are recognized when the employee has rendered service to the company.
7. Income Taxes	Income taxes are recognized when the company has a liability for income taxes.	Income taxes are recognized when the company has a liability for income taxes.
8. Financial Instruments	Financial instruments are recognized when they are issued or acquired.	Financial instruments are recognized when they are issued or acquired.
9. Derivatives	Derivatives are recognized when they are issued or acquired.	Derivatives are recognized when they are issued or acquired.
10. Other	Other items are recognized when they are issued or acquired.	Other items are recognized when they are issued or acquired.

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	50	2202	25	Claims in excess of 20
1201	200	2201	100	Independent claims in excess of 3
1203	360	2203	180	Multiple dependent claim, if not paid
1204	200	2204	100	**Reissue independent claims over original patent
1205	50	2205	25	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)	(\$) -0-
---------------------	-----------------

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

<u>Large Entity</u>	<u>Small Entity</u>
<p>1. Revenue</p> <p>2. Expenses</p> <p>3. Net Income</p> <p>4. Assets</p> <p>5. Liabilities</p> <p>6. Equity</p>	<p>1. Revenue</p> <p>2. Expenses</p> <p>3. Net Income</p> <p>4. Assets</p> <p>5. Liabilities</p> <p>6. Equity</p>

Fee Code	Fee (\$)	Fee Code	Fee (\$)
-------------	-------------	-------------	-------------

1051	130	2051	65	Surcharge - late filing fee or oath or declaration
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet
1053	130	2053	130	Non-English specification
1812	2,520	21812	2,520	For filing a request for <i>ex parte</i> reexamination
1804	920*	21804	920*	Requesting publication of SIR prior to Examiner action
1805	1,840*	21805	1,840*	Requesting publication of SIR after Examiner action
1251	120	2251	60	Extension for reply within first month
1252	450	2252	225	Extension for reply within second month
1253	1020	2253	510	Extension for reply within third month
1254	1,590	2254	795	Extension for reply within fourth month
1255	2,160	2255	1,080	Extension for reply within fifth month
1401	500	2401	250	Notice of Appeal
1402	500	2402	250	Filing a brief in support of an appeal
1403	1000	2403	500	Request for oral hearing
1451	1,510	2451	1,510	Petition to institute a public use proceeding
1452	500	2452	250	Petition to revive - unavoidable
1453	1,500	2453	750	Petition to revive - unintentional
1501	1,400	2501	700	Utility issue fee (or reissue)
1502	800	2502	400	Design issue fee
1503	1100	2503	550	Plant issue fee
1460	—	21460	—	Petitions to the Director
1807	50	21807	50	Processing fee for Provisional Applications
1806	180	21806	180	Submission of Information Disclosure Stmt
8021	40	28021	40	Recording each patent assignment per property (times number of properties)
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))
1801	790	2801	395	Request for Continued Examination (RCE)
1802	900	2802	900	Request for expedited examination of a design application

Other fee (specify) _____

SUBTOTAL (3)	(\$) -0-
---------------------	-----------------

SUBMITTED BY

Name (Print/Type)

Narinder S. Banait

Registration No.
(Attorney/Agent)

43,482

Complete (if applicable)

Telephone 650\335-7306

Signature

Veriade Bonif.

Date _____

July 19/2005

1970-06-06

23946/08185/DOCS/1545074.1

23946/08185/DOCS/1545074.1



PATENT

IN THE UNITED STATES

PATENT AND TRADEMARK OFFICE

APPLICANT: G. Scott Herron
PATENT NO.: 6,906,237
ISSUE DATE: June 14, 2005
SERIAL NO.: 09/905,704
FILING DATE: February 27, 2001
TITLE: In Vivo Assay for Anti Angiogenic Compounds
ATTY. DKT. NO.: 23946-08185

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

Dated: July 19/2005

By: Narinder S. Banait
Narinder S. Banait, Reg. No. 43,482

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

ATTENTION: DECISION AND CERTIFICATE OF CORRECTION
BRANCH OF THE PATENT ISSUE DIVISION

REQUEST FOR CERTIFICATE OF CORRECTION

SIR:

The following errors, as more fully described below, appear in this patent.

☒ The Applicant submits that no fee is due for correction of the errors made by the Patent and Trademark Office; OR,

Attached hereto are duplicate Forms PTO-1050, with at least one copy that is suitable for printing.

Applicant kindly requests the following changes:

In the Title: please replace "Vivo" with --In Vivo--

REC 9 6 2005

Claim 1, Column 15, Line 59: please replace "inmuno" with --immuno--

Claim 5, Column 16, Line 3: please replace "(eGEP)" with --(eGFP)--

Please send the Certificate to:

Narinder S. Banait, Reg. No. 43,482
Fenwick & West LLP
801 California Street
Mountain View, CA 94041

Respectfully submitted,
G. Scott Herron

Dated: July 19/2005

By: Narinder S. Banait
Narinder S. Banait, Reg. No. 43,482
Fenwick & West LLP
801 California Street
Mountain View, CA 94041
Telephone: 650-335-7818
Facsimile: 650-938-5200
E-mail: nbanait@fenwick.com

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,906,237

DATED : June 14, 2005

INVENTOR : G. Scott Herron

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Title: Please replace "Vivo" with --In Vivo--

Claim 1, Column 15, Line 59: please replace "inmuno" with --immuno--

Claim 5, Column 16, Line 3: please replace "(eGEP)" with --(eGFP)--

MAILING ADDRESS OF SENDER:

PATENT NO. _____

No, of add'l copies
@50¢ per page



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,906,237
DATED : June 14, 2005
INVENTOR : G. Scott Herron

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Title: Please replace "Vivo" with --In Vivo--

Claim 1, Column 15, Line 59: please replace "inmuno" with --immuno--

Claim 5, Column 16, Line 3: please replace "(eGEP)" with --(eGFP)--

MAILING ADDRESS OF SENDER:

PATENT No. _____

No. of add'l copies
@50¢ per page



JUN 26 2005

23946/08185/DOCS/1544925.1